상세 보기
Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
- Yoon, Dok Hyun;
- Koh, Youngil;
- Jung, Miyoung;
- Kwak, Jeong-Eun;
- Shin, Eui-Cheol;
- ... Kim, Won Seog;
- 외 1명
WEB OF SCIENCE
9SCOPUS
11초록
The prognosis of non-Hodgkin lymphoma (NHL) remains poor, with an unmet need for novel therapies. MG4101, an ex vivo-expanded allogeneic natural killer (NK) cell, can enhance rituximab antibody-dependent cytotoxicity in relapsed/refractory (r/r) B cell non-Hodgkin lymphoma. This study assessed the safety and efficacy of MG4101 plus rituximab for patients with r/r NHL. Patients received escalating doses of i.v. MG4101 plus rituximab every 2 weeks. IL-2 was administered s.c. after MG4101 treatment. Fludarabine plus cyclophosphamide was administered i.v. before rituximab treatment in cycles 1, 3, and 5. A 3+3 design was used to determine the maximum tolerated dose (MTD) and maximum feasible dose. Assessments were performed over a 6-cycle period, with an extended maintenance period of up to 8 cycles. Nine patients received 3 different doses of MG4101 and rituximab. MTD could not be determined because of the absence of dose-limiting toxicity. Treatment-related adverse events, mostly grade 1 or 2, occurred in 89% of patients. Only 1 patient experienced grade 1 cytokine release syndrome. MG4101 persisted for at least 7 days in 7 patients. Four patients achieved a partial response and 1 patient attained a complete response, for an overall response rate of 55.6%. Two patients showed prolonged responses and low exhaustion marker levels in T cells. For allogeneic NK cell therapy, strategies including the use of the high-affinity hFc gamma RIIIaV158 variant of the KIR B/x haplotype with lymphodepleting chemotherapy may be promising options for improving clinical efficacy in the antibody combination therapeutic setting as an off-the-shelf product. MG4101 plus rituximab presented a favorable safety profile and overall response rate in patients with r/r NHL (c) 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
키워드
- 제목
- Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
- 저자
- Yoon, Dok Hyun; Koh, Youngil; Jung, Miyoung; Kwak, Jeong-Eun; Shin, Eui-Cheol; Hwang, Yu Kyeong; Kim, Won Seog
- 발행일
- 2023-04
- 유형
- Article
- 권
- 29
- 호
- 4
- 페이지
- 253e1 ~ 253e9
- 언어
- ENG
- 출판사
- ELSEVIER SCIENCE INC
- 발행국가
- 미국
- ISSN
- E 2666-6367
P 2666-6375